BioStock Studio: Cereno Scientific’s CEO about the milestone in the CS1...

Last week, Spotlight-listed Cereno Scientific got the acceptance from the FDA regarding their IND application for initiating a phase II trial with CS1 in...
Abliva's NV354 to progress to clinical development

Abliva’s NV354 to progress to clinical development

Biopharma company Abliva ended last week on a high note when it announced positive feedback from the MHRA, the UK regulatory authority, regarding its...

BioStock Studio: Immunicum’s CEO on the company’s new therapeutic focus

Swedish immunotherapy company Immunicum has broadened its cancer treatment focus with the addition of drug candidate DCP-001 thanks to the merger with Dutch biotech...

Lipum is at the final step before clinical phase

Late last week, Lipum announced that the toxicology and safety studies with the drug candidate SOL-116 are proceeding according to plan. The company has...
Nytt projekt för Sprint Bioscience

A new cancer project in Sprint Bioscience’s portfolio

In connection with the rights issue this summer, the biotechnology company Sprint Bioscience promised further investments in expanding the development portfolio. Now, about a...

Chordate Medical resumes initiative with Nanos Medical in China

Chordate Medical is making progress in China with K.O.S. rhinitis treatment. The company has received a prepaid order for two new-generation K.O.S. devices from...

Targinta’s new CEO has started

On September 1, Per Norlén took on the role of CEO of Targinta, Xintela's oncology subsidiary, which is being prepared to be spun off...
Patent approval stamp

Patent approved for Respiratorius’ COPD project

Lund-based Respiratorius has received the green light from the European Patent Office regarding the company's patent application for the RESP9000 series. The company has...

Elicera Therapeutics comes out of the gate running in Q2

For Swedish immuno-oncology company Elicera Therapeutics, the highlight of Q2 was going public and being listed on Nasdaq First North Growth Market, all while...
RhoVac är snart klara med sin rekrytering

Completion of the recruitment for RhoVac’s Phase IIb study expected in...

RhoVac continued its work on the drug candidate RV001 in the second quarter and was able to present several news items in the project....